Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(2.25)
# 2,762
Out of 5,131 analysts
10
Total ratings
50%
Success rate
11.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $1.77 | +351.98% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $25.97 | -3.74% | 1 | May 14, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $47 | $12.88 | +264.91% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $2.50 | +100.00% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $44.67 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $3.73 | +489.81% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $27.30 | +317.58% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $10.79 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.77
Upside: +351.98%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $25.97
Upside: -3.74%
Astria Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $47
Current: $12.88
Upside: +264.91%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $2.50
Upside: +100.00%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $44.67
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $3.73
Upside: +489.81%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $27.30
Upside: +317.58%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $10.79
Upside: -